文献速递血液净化与透析

静脉用重组人促红素α仿制药与重组人促红素α治疗终末期肾病贫血的对比研究

Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-06-19

该24周多中心双盲研究纳入612例血红蛋白稳定且接受稳定剂量静脉重组人促红素α的血液透析合并贫血的终末期肾病患者,随机1:1接受重组人促红素α或重组人促红素α仿制药。结果显示两组周均血红蛋白水平和周均每公斤体重促红素剂量的最小二乘均值差异的95%置信区间均在预设等效界值内,不良事件、严重不良事件和死亡发生率相似,无中和抗体或纯红细胞再生障碍性贫血事件。

要点

  • 重组人促红素α仿制药与重组人促红素α在血红蛋白水平和促红素剂量上达到等效。
  • 两组不良事件、严重不良事件及死亡发生率相似,安全性无临床意义差异。
  • 未观察到中和抗体或纯红细胞再生障碍性贫血事件。

核心结论

  • 在血液透析合并贫血的终末期肾病患者中,重组人促红素α仿制药与重组人促红素α在疗效和安全性方面无临床意义差异。

研究设计与样本

  • 24周、多中心、双盲、对照的疗效与安全性研究,纳入612例血红蛋白稳定且接受稳定剂量静脉重组人促红素α的血液透析合并贫血的终末期肾病患者,随机1:1分组。

主要发现

  • 重组人促红素α仿制药与重组人促红素α的周均血红蛋白最小二乘均值差异为-0.12 g/dl(95%CI -0.25至0.01),落在预设等效界值(-0.5至0.5 g/dl)内。
  • 两组周均每公斤体重促红素剂量的最小二乘均值差异为0.37 U/kg/周(95%CI -10.40至11.13),落在预设等效界值(-45至45 U/kg/周)内。
  • 重组人促红素α仿制药组与重组人促红素α组的不良事件发生率分别为77.1%和75.3%,严重不良事件发生率分别为24.9%和27.0%,死亡例数分别为5例和6例。
  • 基线有5例患者抗重组人促红素抗体阳性,研究期间两组各1例新发抗重组人促红素抗体,所有患者中和抗体检测均为阴性,无纯红细胞再生障碍性贫血事件。

临床怎么用

  • 重组人促红素α仿制药可作为重组人促红素α的等效替代用于血液透析合并贫血的终末期肾病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: This study was conducted to compare the safety and efficacy of intravenous epoetin alfa-epbx, an epoetin alfa biosimilar, to epoetin alfa in patients on hemodialysis with ESKD and anemia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 24-week, multicenter, double-blind comparative efficacy and safety study, 612 patients on hemodialysis with ESKD and anemia who had stable hemoglobin and were receiving stable doses of intravenous epoetin alfa were randomized (1:1) to intravenous epoetin alfa or epoetin alfa-epbx. Dosing was adjusted according to the epoetin alfa prescribing information. The coprimary efficacy end points were the least squares mean difference between the two treatments in mean weekly hemoglobin level and mean weekly epoetin dose per kilogram of body weight during the last 4 weeks of treatment. RESULTS: The least squares mean difference between epoetin alfa-epbx and epoetin alfa in weekly hemoglobin was -0.12 g/dl and the 95% confidence interval (-0.25 to 0.01) was contained within the prespecified equivalence margin (-0.5 to 0.5 g/dl). The least squares mean difference between epoetin alfa-epbx and epoetin alfa in weekly epoetin dose per kilogram of body weight was 0.37 U/kg per week, and the 95% confidence interval (-10.40 to 11.13) was contained within the prespecified equivalence margin (-45 to 45 U/kg per week). Incidences of adverse events (77.1% versus 75.3%), serious adverse events (24.9% versus 27.0%), and deaths (n=5 versus 6) were similar between the epoetin alfa-epbx and epoetin alfa groups, respectively. Five patients tested positive for anti-recombinant human erythropoietin antibodies at baseline, and two additional patients (n=1 per group) developed anti-recombinant human erythropoietin antibodies while on study treatment. All patients tested negative for neutralizing antibodies, and no patient in either group experienced an event of pure red cell aplasia. CONCLUSIONS: This 24-week, comparative, clinical trial in patients on hemodialysis with ESKD and anemia demonstrated there is no clinically meaningful difference in efficacy or safety between epoetin alfa-epbx and epoetin alfa.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Fishbane S, Singh B, Kumbhat S, et al. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 29921734. doi:10.2215/CJN.11631017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。